Cyclerion Therapeutics, Inc.
CYCN
$1.53
$0.000.00%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1,371.65% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,371.65% | -- | -- | -- | -- |
| Cost of Revenue | 116.65% | 92.52% | 98.48% | -- | -155.62% |
| Gross Profit | 81.79% | 192.78% | 295.64% | -- | 164.18% |
| SG&A Expenses | -1.20% | -18.04% | -26.83% | -35.88% | -39.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.03% | -21.03% | -30.55% | -41.65% | -50.28% |
| Operating Income | 38.68% | 49.99% | 56.60% | 62.39% | 51.85% |
| Income Before Tax | 58.36% | 81.41% | 73.11% | 75.72% | 65.30% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 58.36% | 81.41% | 73.11% | 75.72% | 65.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -100.00% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 58.36% | -164.69% | -2,075.84% | 41.92% | 51.03% |
| EBIT | 38.68% | 49.99% | 56.60% | 62.39% | 51.85% |
| EBITDA | -- | -- | -- | -- | 85.49% |
| EPS Basic | 64.23% | -158.35% | -3,393.99% | 53.17% | 59.53% |
| Normalized Basic EPS | 44.02% | 59.68% | 63.27% | 69.54% | 60.08% |
| EPS Diluted | 64.24% | -158.38% | -3,322.06% | 53.18% | 59.52% |
| Normalized Diluted EPS | 44.02% | 59.68% | 63.27% | 69.54% | 60.08% |
| Average Basic Shares Outstanding | 14.11% | 8.10% | 4.84% | 7.74% | 10.14% |
| Average Diluted Shares Outstanding | 14.11% | 8.10% | 4.84% | 7.74% | 10.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |